Internalisation of uncross-linked rituximab is not essential for the induction of caspase-independent killing in Burkitt lymphoma cell lines

J Turzanski, I Daniels, AP Haynes - Leukemia & lymphoma, 2008 - Taylor & Francis
Characterising the mechanisms underpinning caspase-independent programmed cell death
(CI-PCD) induction by uncross-linked rituximab in B-cells may positively impact upon the …

Caspase-independent killing of Burkitt lymphoma cell lines by rituximab

I Daniels, AM Abulayha, BJ Thomson, AP Haynes - Apoptosis, 2006 - Springer
Caspase-independent cell death may have a critical role to play in the therapeutic
destruction of tumours. Recently it has been suggested that one of the mechanisms by which …

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

C Stolz, G Hess, PS Hähnel, F Grabellus… - Blood, The Journal …, 2008 - ashpublications.org
The chimeric monoclonal antibody rituximab is the standard of care for patients with B-cell
non-Hodgkin lymphoma (B-NHL). Rituximab mediates complement-dependent cytotoxicity …

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

B Li, L Zhao, H Guo, C Wang, X Zhang… - Blood, The Journal …, 2009 - ashpublications.org
Despite widespread use of the anti-CD20 monoclonal antibody (mAb), rituximab, in treating
B-cell lymphomas, its efficacy remains variable and often modest. A better understanding of …

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

O Manches, G Lui, L Chaperot… - Blood, The Journal …, 2003 - ashpublications.org
To assess the sensitivity of primary non-Hodgkin lymphoma cells to rituximab-mediated
cytotoxicity, we compared the potency of several rituximab-mediated killing mechanisms on …

A requirement for calcium in the caspase‐independent killing of Burkitt lymphoma cell lines by Rituximab

I Daniels, J Turzanski… - British journal of …, 2008 - Wiley Online Library
The therapeutic monoclonal antibody rituximab has previously been shown to kill B cells in a
caspase‐independent manner. The signalling pathways underpinning this novel death …

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

SH Olejniczak, FJ Hernandez-Ilizaliturri… - Clinical cancer …, 2008 - AACR
Purpose: Targeting malignant B cells using rituximab (anti-CD20) has improved the efficacy
of chemotherapy regimens used to treat patients with non-Hodgkin's lymphoma. Despite the …

[HTML][HTML] Rituximab and Obinutuzumab induce direct B-cell death via B-cell receptor (BCR) signaling, but Rituximab elicits stronger BCR-derived pro-survival signals …

J Edelmann, A Dokal, K Holzmann, DJ Britton… - Blood, 2019 - Elsevier
The anti-CD20 monoclonal antibody (mAb) rituximab in combination with chemotherapy has
improved outcomes for patients with CD20+ B-cell lymphoma. Obinutuzumab was …

Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro

A Furlan, F Villanova, F Pietrogrande… - Leukemia & …, 2010 - Taylor & Francis
Rituximab maintenance therapy provides a significant benefit in patients with indolent B-cell
non-Hodgkin lymphoma (NHL). Based on its efficacy in improving response to …

Rituximab increases the cytotoxicities of vincristine and hydroxyurea through caspase-dependent and caspase-independent cell death, respectively

S Tabal, A Elbanani, M Deyab… - Cancer Biotherapy and …, 2015 - liebertpub.com
In the treatment of B cell non-Hodgkin's lymphoma, rituximab is used in combination with
different chemotherapeutics to improve its efficacy, but the mechanisms involved are not fully …